An observational study in Obstructive Sleep Apnea and Periodic Leg Movements, Excessive, Sleep-Related, sponsored by Acurable Ltd.. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Acurable Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Sleep Apnea, Obstructive with a site in Spain — 16 open to participants now, 19 under way, 6 of them phase 3. Sleep Apnea, Obstructive · Spain.
Among the 82 studies in Sleep Apnea, Obstructive with a site in Spain, this one is the 13th largest by planned enrollment of the 21 observational ones that give a count, is one of 15 that started in 2019, is one of 21 observational ones, reaches primary completion later than 18 of the 18 other live ones, and was the 41st registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →16 of the 82 studies in Sleep Apnea, Obstructive with a site in Spain are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Australia and 8 more countries
Ages 18+
Sociedad Española de Neumología y Cirugía Torácica · Sites in Spain
Ages 18+
Hospital Clinic of Barcelona · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 15 started in 2019.
This study's planned enrollment of 296 is above the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 128 across the 60 interventional studies, 338 across the 21 observational. Of the 44 that completed or were terminated, 3 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 82 have an industry lead sponsor. The 10 most frequent:
Acurable Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Acurable Ltd. has 2 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
3 of the studies in Sleep Apnea, Obstructive with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07001215Hospital Universitario Ramon y CajalEffect of CPAP Versus APAP in Patients With Obesity Undergoing Bariatric Surgery Protocol | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 82 studies in Sleep Apnea, Obstructive with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial will aim to test a new wearable device for the diagnosis of Sleep Apnoea.
This clinical trial will test a new wearable device for the diagnosis of Sleep Apnoea against Multi-channel polygraphy and Polysomnography.
For Group 1 and Group 2, the patients who have been referred for a sleep apnoea diagnosis will undergo in-hospital overnight polysomnography while wearing the new wearable device. Performance (i.e. sensitivity and specificity) of the new device will be assessed against the gold standard system.
For Group 3 and 4, the patients who have been referred for a sleep apnoea diagnosis will undergo in-hospital overnight polysomnography while wearing the new wearable device and a CE-marked oximeter.
For Group 5, patients presenting clinical criteria of Restless Legs Syndrome who are being evaluated via sleep studies as part of a routine clinical care will undergo an overnight polysomnography while wearing the new wearable device system.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Patients who have been referred for suspicion of sleep apnoea
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
75 patients will wear polysomnography at the same time as the Novel wearable device
Diagnostic Test: Novel Wearable device
51 patients (plus up to 20% to account for possible dropouts) will wear polysomnography at the same time as the novel wearable device and a CE-marked pulse-oximeter.
Diagnostic Test: Novel Wearable device
Additional 75 consecutive patients will wear polysomnography at the same time as the novel wearable device and a CE-marked pulse-oximeter.
A first group of \~10-15 patients will be recruited, chosen from those who have been referred for a sleep apnea diagnosis. This group will not be used for performance validation, but rather to train all relevant staff on the different steps of the protocol and for the initial investigation of some of the secondary objectives related to usability.
70 patients presenting clinical criteria compatible with Restless legs Syndrome and who are being evaluated for a sleep study as part of their routine clinical care will be included. The patients will wear standard polysomnography while simultaneously wearing the new wearable system (a total of 4 sensors: 1 sensor on the neck, 1 pulse oximeter on finger, and 1-2 sensors on the legs).
patient will wear novel wearable device overnight along with normal standard of care
Sensitivities and Specificity for diagnosis of sleep apnoea studies with novel wearable device
The study aims to compare the diagnosis result of the novel wearable device against standard of care
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2019 (actual). Primary completion is estimated for Dec 2028, 111 months after the start.
Of 36 industry-sponsored observational studies under Sleep Apnea, Obstructive, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 93. This study's planned 111 months is above that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2024 → Dec 2028 and completion Dec 2024 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acurable Ltd.